Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Application (C.difficle, Crohns disease, IBS, Diabetes, and Others), By Product (APIs, FDFs), By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, and Others), By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations), By Region and Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.

Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly available live biotherapeutics products available in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.

A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.

Increasing Prevalence of Chronic Diseases
Chronic diseases are defined broadly as conditions that progress slowly and persist over an extended period. Some of the major risk factors which lead to the development of chronic illness inside human body include intake of unbalanced diet, consumption of alcohol, smoking cigarettes, physical inactivity, and others. Cardiovascular diseases, Cancer, and diabetes are three most prevailing chronic diseases in the world which are thereby increasing the mortality of every country in the forecast period. According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world.  After cardiovascular diseases, cancer has been reported as second major reason behind the growing mortality rate of various developing countries across the world. As per the report published by World Health Organization (WHO) in 2022, it has been observed that lung cancer has been the most prominent type of cancer prevailing across the world accounting for 1.80 million deaths, followed by 9,16,000 deaths caused by colon and rectum cancer, 8,30,000 deaths due to liver cancer, 7,69,000 deaths by stomach cancer and 6,85,000 deaths caused by breast cancer. Live biotherapeutic products are designed to modulate the gut microbiome which plays a major role in maintaining a healthy immune system and preventing chronic diseases. Moreover, microbe CDMOs provide customized solutions for the development, manufacturing, and scale-up of microbial products for clinical trials and commercial use. Other health problems which can affect the human body along with prevalence of chronic diseases are expected to propel the growth of global biotherapeutics products and microbe CDMO market in the forecast period.


Download Free Sample Report

Rise in Demand for Personalized Medicines
The growing demand for personalized medicines is indeed a significant driver of the global biotherapeutics products and microbe CDMO (Contract Development and Manufacturing Organization) market. Biotherapeutics products, including personalized medicines, are a major growth area of pharmaceutical industry. These products are derived from biological sources, such as living cells, and can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Moreover, microbe CDMOs are specialized in the development and manufacturing of biotherapeutics products, including personalized medicines, using microbial systems such as bacteria, yeast, and fungi. These CDMOs offer a range of services, including cell line development, process development, analytical development, and manufacturing. The growing demand for personalized medicines has led to an increase in the demand for these services which are further projected to register an impressive growth to Global Biotherapeutics Products and Microbe CDMO market in upcoming years.

Recent Developments

  • In Nov 2021, Bacthera and Seres Therapeutics announced a collaboration to manufacture SER-109, Seres' lead product candidate for recurrent Clostridioides difficile infection (CDI). Under the terms of the agreement, Bacteria is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of s located on Lonza's Ibex campus in Visp, Switzerland. The agreement between Bacthera and Seres Therapeutics aims to expand upon Seres' initial commercial manufacturing supply chain.
  • In May 2021, Bacthera's drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera's drug substance facility in Hørsholm, Denmark, both facilities had been granted manufacturing licenses by the respective national health authorities. The permit allow the Company to fulfill the scope of bringing innovative Live Biotherapeutic Products (LBP) to patients with unmet medical needs.
  • In Nov 2019, Arranta Bio has received an US$82 million funding round and a strategic partnership with Thermo Fisher Scientific.Through this partnersship with Thermo Fisher, Arranta has access to the company's a wide range of product portfolio and services and provided materials to Thermo Fisher for use in gene therapy production.
  • In Oct 2019, 4D pharma plc announced research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc. to discover and develop Live Biotherapeutics ("s") for vaccines. Through this agreement, 4D's proprietary MicroRx platform will be paired with MSD's expertise in developing and commercializing novel vaccines to discover and develop s as vaccines in up to three undisclosed indications.
  • In April 2019, Chr. Hansen Holding A/S and Lonza AG equally shared approximately €90m ($101.5m) to establish a CDMO (contract development and manufacturing organization) for biotherapeutic products. The investment was in two phases, bagan with an update to Lonza's existing facilities in Hørsholm, Denmark, for cGMP production of drug substances (anaerobic bacteria). It has equipped new facilities in Basel, Switzerland, for drug product development and manufacturing.
  • In July 2022, Quay Pharma and SGS worked together to create a novel oral treatment for inflammatory bowel disease. Millions of people with Crohn's disease and ulcerative colitis may make a difference in their lives because of this new oral medication. For pharmaceutical and biotechnology firms worldwide, SGS's Quay Pharma offers a complete outsourcing service for formulation and analytical development, followed by clinical trials and commercial manufacture.
  • In June 2020, to broaden the microbial platform and increase the flexibility of probiotic manufacturing, Chr. Hansen acquired UAS Laboratories LLC. The acquisition does not affect the company's ability to pay an ordinary dividend of between 40% and 60% of net profit and is entirely consistent with Chr. Hansen's capital allocation policies. Low interest bridging financing from core banks will be used to pay the acquisition price.
  • In Apr 2019, Catalent, Inc., Paragon Bioservices, Inc., and Catalent Inc. announced that they had signed a legally binding agreement under which Catalent would pay $1.2 billion to purchase Paragon. The deal will provide Catalent's stockholders with desirable value, and Paragon will represent a modest portion of Catalent's business in the short term. Still, over time, the acquisition will change the company's business profile and significantly speed up sales and EBITDA growth.

Market Segmentation
Global live biotherapeutics products and microbe CDMO market is segmented based on application, product, type of formulation, scale of operation, company, and region. In terms of application, the live biotherapeutics products and microbe CDMO market is categorized into C.difficle, Crohns disease, IBS, diabetes, and others. Based on product, the global live biotherapeutics products and microbe CDMO market is fragmented into APIs and FDFs. Based on type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on scale of operation, the global live biotherapeutics products and microbe CDMO market is fragmented into preclinical scale operations, clinical scale operations, and commercial scale operations.

Market Players
Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are the major players of global live biotherapeutics products and microbe CDMO market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Application

Product

Type of Formulation

Scale of Operation

Regional scope

North America; Asia Pacific; Europe; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia;

Key companies profiled

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, Inpac Probiotics

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Report Scope:
In this report, Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         Live Biotherapeutics Products and Microbe CDMO Market, By Application:

o   C.difficle

o   Crohns disease

o   IBS

o   Diabetes

o   Others

·         Live Biotherapeutics Products and Microbe CDMO Market, By Product:

o   APIs

o   FDFs

·         Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation:

o   Solid Formulations

o   Oral Liquids

o   Injectables

o   Others

·         Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation:

o   Preclinical Scale Operations

o   Clinical Scale Operations

o   Commercial Scale Operations

·         Live Biotherapeutics Products and Microbe CDMO Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Live Biotherapeutics Products and Microbe CDMO Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Live Biotherapeutics Products and Microbe CDMO Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Live Biotherapeutics Products and Microbe CDMO Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value & Volume

5.2.  Market Share & Forecast

5.2.1.     By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)

5.2.2.     By Product (APIs, FDFs)

5.2.3.     By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)

5.2.4.     By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)

5.2.5.     By Region

5.2.6.     By Company (2022)

5.3.  Product Market Map 

6.    North America Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value & Volume

6.2.  Market Share & Forecast

6.2.1.     By Application

6.2.2.     By Product

6.2.3.     By Type of Formulation

6.2.4.     By Scale of Operation

6.2.5.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value & Volume

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Application

6.3.1.2.2. By Product

6.3.1.2.3. By Type of Formulation

6.3.1.2.4. By Scale of operation

6.3.2.     Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value & Volume

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Application

6.3.2.2.2. By Product

6.3.2.2.3. By Type of Formulation

6.3.2.2.4. By Scale of Operation

6.3.3.    Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value & Volume

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Application

6.3.3.2.2. By Product

6.3.3.2.3. By Type of Formulation

6.3.3.2.4. By Scale of Operation

7.    Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Application

7.2.2.     By Product

7.2.3.     By Type of Formulation

7.2.4.     By Scale of Operation

7.3   Europe: Country Analysis

7.3.1.    France Live Biotherapeutics Products and Microbe CDMO Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value & Volume

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Application

7.3.1.2.2. By Product

7.3.1.2.3. By Type of Formulation

7.3.1.2.4. By Scale of Operation

7.3.2.    Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value & Volume

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Application

7.3.2.2.2. By Product

7.3.2.2.3. By Type of Formulation

7.3.2.2.4. By Scale of Operation

7.3.3.    United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value & Volume

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Application

7.3.3.2.2. By Product

7.3.3.2.3. By Type of Formulation

7.3.3.2.4. By Scale of Operation

7.3.4.    Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value & Volume

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Application

7.3.4.2.2. By Product

7.3.4.2.3. By Type of Formulation

7.3.4.2.4. By Scale of Operation

7.3.5.    Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value & Volume

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Application

7.3.5.2.2. By Product

7.3.5.2.3. By Type of Formulation

7.3.5.2.4. By Scale of Operation

8.    Asia-Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value & Volume

8.2.  Market Share & Forecast

8.2.1.     By Application

8.2.2.     By Product

8.2.3.     By Type of Formulation

8.2.4.     By Scale of Operation

8.2.5.     By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.     China Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value & Volume

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Application

8.3.1.2.2. By Product

8.3.1.2.3. By Type of Formulation

8.3.1.2.4. By Scale of Operation

8.3.2.     India Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value & Volume

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Application

8.3.2.2.2. By Product

8.3.2.2.3. By Type of Formulation

8.3.2.2.4. By Scale of Operation

8.3.3.     South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value & Volume

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Application

8.3.3.2.2. By Product

8.3.3.2.3. By Type of Formulation

8.3.3.2.4. By Scale of Operation

8.3.4.     Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value & Volume

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Application

8.3.4.2.2. By Product

8.3.4.2.3. By Type of Formulation

8.3.4.2.4. By Scale of Operation

8.3.5.     Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value & Volume

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Application

8.3.5.2.2. By Product

8.3.5.2.3. By Type of Formulation

8.3.5.2.4. By Scale of Operation

9.    South America Live Biotherapeutics Products and Microbe CDMO Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value & Volume

9.2.  Market Share & Forecast

9.2.1.     By Application

9.2.2.     By Product

9.2.3.     By Type of Formulation

9.2.4.     By Scale of Operation

9.2.5.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value & Volume

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Application

9.3.1.2.2. By Product

9.3.1.2.3. By Type of Formulation

9.3.1.2.4. BY Scale of Operation

9.3.2.     Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value & Volume

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Application

9.3.2.2.2. By Product

9.3.2.2.3. By Type of Formulation

9.3.2.2.4. By Scale of Operation

9.3.3.     Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value & Volume

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Application

9.3.3.2.2. By Product

9.3.3.2.3. By Type of Formulation

9.3.3.2.4. By Scale of Operation

10.  Middle East and Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

10.1.  Market Size & Forecast

10.1.1.  By Value & Volume

10.2.              Market Share & Forecast

10.2.1.  By Application

10.2.2.  By Product

10.2.3.  By Type of Formulation

10.2.4.  By Scale of Operation

10.2.5.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1.  By Value & Volume

10.3.1.2. Market Share & Forecast

10.3.1.2.1.  By Application

10.3.1.2.2.  By Product

10.3.1.2.3.  By Type of Formulation

10.3.1.2.4.  By Scale of Operation

10.3.2.  Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1.  By Value & Volume

10.3.2.2. Market Share & Forecast

10.3.2.2.1.  By Application

10.3.2.2.2.  By Product

10.3.2.2.3.  By Type of Formulation

10.3.2.2.4.  By Scale of Operation

10.3.3.  UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook

10.3.3.1.Market Size & Forecast

10.3.3.1.1.  By Value & Volume

10.3.3.2. Market Share & Forecast

10.3.3.2.1.  By Application

10.3.3.2.2.  By Product

10.3.3.2.3.  By Type of Formulation

10.3.3.2.4.  By Scale of Operation

11.  Market Dynamics

11.1.  Drivers

11.2.  Challenges

12.  Market Trends & Developments

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

14.1.  Competition in the Industry

14.2.  Potential of New Entrants

14.3.  Power of Suppliers

14.4.  Power of Customers

14.5.  Threat of Substitute Product

15.  Competitive Landscape 

15.1.    Business Overview

15.2.    Company Snapshot

15.3.    Products & Services

15.4.    Financials (In case of listed companies)

15.5.    Recent Developments

15.6.    SWOT Analysis

15.6.1.  Arranta Bio Holdings LLC.

15.6.2.  4D Pharma plc. 

15.6.3.  Cerbios-Pharma S.A.

15.6.4.  Biose Industrie

15.6.5.  Assembly Biosciences, Inc.

15.6.6.  Wacker Chemie AG

15.6.7.  Quay Pharmaceuticals Ltd.

15.6.8.  Bacthera AG

15.6.9.  LONZA

15.6.10.  Inpac Probiotics

16.  Strategic Recommendations

17.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

Growing prevalence of various chronic diseases such as diabetes, cancer, cardiovascular, and other diseases across the world are driving the demand for the global live biotherapeutics products and microbe CDMO market.

down-arrow

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are some of the key players operating in the global live biotherapeutics products and microbe CDMO market.

down-arrow

Growing preference of people towards personalized medicines for management of their health-related problems is affecting the growth of the global live biotherapeutics products and microbe CDMO market in the forecast period.

down-arrow

Based on application, C.difficle is dominating the market and is expected to maintain its dominance over the next five years owning to increase in interest of people in using live biotherapeutic products (LBPs) to treat a range of diseases, including those related to the gut microbiome.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Live Biotherapeutics Products and Microbe CDMO Market is Expected to Grow at a High CAGR Through 2028

Aug, 2023

Increasing awareness of the importance of microbiome and initiatives taken by government to improve the healthcare infrastructure in their respective country are the major drivers for the global live

Why Choose Us